2/12/2015 8:30:00 AM

Bayer develops new insecticide for malaria vector control

During a recent meeting of the Roll Back Malaria Vector Control Working Group on insecticide resistance; Pedro Alonso, Director of the WHO Global Malaria Program said in Geneva that(Insecticide resistance) is the greatest current threat to the future of malaria control and to the sustainability of the achievements of recent years’. With more than half of the international funding for malaria control being spent on vector control commodities or activities, resistance by malaria transmitting mosquitoes to the limited range of insecticides currently recommended by the WHO is clearly a major problem.

With only one insecticide family currently recommended for use on long-lasting insecticide-treated nets and resistance to this group of compounds now being widespread, the use of alternative insecticides for indoor residual spraying has gained increased interest in recent years. There are however, only a limited range of options available for this intervention technique as well. In 2012 the WHO launched its Global Plan for Insecticide Resistance Management in malaria vectors (GPIRM), which called for a collective strategy in order to maintain the long-term effectiveness of vector control. Within this plan, one of the five key pillars was the ‘development of new innovative vector control tools’; a responsibility which was seen to lie firmly with manufacturers and Product Development Partnerships (eg. the IVCC).

In light of the situation described above, Bayer is pleased to announce significant progress in the development of a new mode of action for malaria vector control. Not only will this new product introduce an insecticide mode of action which is not yet present in malaria vector control (a chloronicotinyl insecticide) but it will do so as a combination product with another unrelated mode of action.

This follows good results in laboratory trials against multiple resistant strains of mosquitoes and initial field trials started in Africa during 2013. A significant expansion of our trial program over the coming 24 months will provide further confirmation where and how this new product can best fit into malaria vector control programs, the impact it will have in managing resistance to existing compounds and how that will improve the lives of those at risk from this disease. The use of all such products is subject to stringent safety and efficacy evaluation within the WHO Pesticides Evaluation Scheme (WHOPES) and Bayer plans to submit a dossier for evaluation of this new product, to WHOPES, in 2015.

The development of this new insecticide for indoor residual spraying against malaria vectors is one example of a number of ongoing vector control projects at Bayer - reflecting a near five-fold increase in our investment into vector control new product development over the last 10 years and part of our commitment to help overcome the threat that insecticide resistance presents to malaria control.

To keep up to date with these developments follow us on Twitter @BayerMalaria